Presentation is loading. Please wait.

Presentation is loading. Please wait.

Axel Linke University of Leipzig Heart Center, Leipzig, Germany

Published byCamilla Hoover Modified over 6 years ago

Similar presentations

Presentation on theme: "Axel Linke University of Leipzig Heart Center, Leipzig, Germany"— Presentation transcript:

1 Treatment of High Risk Aortic Stenosis Patients with Transcatheter Medtronic CoreValve Implantation
Axel Linke University of Leipzig Heart Center, Leipzig, Germany Ulrich Gerckens Gemeinschaftskrankenhaus Bonn, Bonn, Germany Peter Wenaweser University Hospital Bern, Bern, Switzerland Corrado Tamburino Ferrarotto Hospital, University of Catania, Catania, Italy Johan Bosmans University Hospital Antwerp, Antwerp Belgium Stephen Brecker St. George’s Hospital, London, United Kingdom Robert Bauernschmitt ISAR Heart Center, Munich, Germany (on behalf of the ADVANCE Investigators) This slide deck focuses on the CoreValve® (Medtronic, Inc., Minneapolis, MN) Percutaneous Aortic Valve Replacement System and provides a summary of the clinical experience regarding its benefits, risks, and potential use as an alternative to surgical aortic valve replacement.

2 CoreValve ADVANCE | Background
Transcatheter Aortic Valve Implant (TAVI) enables treatment of aortic valve stenosis without open-heart surgery. Balloon-expandable TAVI - superior to standard medical therapy in inoperable patients - non-inferior to surgical AVR in high-risk patients with AS in a randomized controlled trial. Neither balloon-expandable or self expanding TAVI have been studied in a rigorous, monitored, independently adjudicated, ‘real world’ study.

3 CoreValve ADVANCE | Background
Medtronic CoreValve® System Porcine pericardial tissue valve sutured into a self expanding nitinol frame Supra-annular valve position preserves circularity at level of valve function 18Fr catheter delivery system 3 valve sizes 3 3 3

4 CoreValve ADVANCE | Objective
The objective of the CoreValve ADVANCE study is to evaluate the safety efficacy clinical outcome according to VARC of percutaneous aortic valve implantation using the Medtronic CoreValve System in consecutive ‘real world’ patients with severe aortic stenosis considered inoperable or high risk for conventional AVR by the local ‘HEART TEAM’.

5 CoreValve ADVANCE | Methods
1,015 patients enrolled from March 2010 to July 2011 5 year follow-up 44 centers - 12 countries in Western Europe, Asia and South America All centers had conducted at least 40 TAVI procedures prior to the study and had Heart Team in place Clinical endpoints reported according to Valve Academic Research Consortium (VARC)

6 CoreValve ADVANCE | Primary Endpoint
Primary Endpoint- Major Adverse Cardiac & Cerebrovascular Events (MACCE) at 30-days post procedure. MACCE defined as a composite of All cause mortality Myocardial Infarction (Q-wave and non-Q-wave) Emergent cardiac surgery or percutaneous re-intervention Stroke Clinical endpoints reported according to VARC All-cause and Cardiovascular Mortality Myocardial Infarctions Life Threatening Bleeding Major Vascular Complications Acute Kidney Injury

7 CoreValve ADVANCE | Study Oversight
100% of all Patients were monitored All Primary Endpoint events adjudicated by an Independent Clinical Events Committee (CEC) Consisting of TAVI-experienced Interventional Cardiologists and Cardiac Surgeon All Cerebrovascular events adjudicated by an Independent Neurologist Adjudication of events utilized all available relevant source documents; including neuroimaging and systematic NIH Stroke Scale assessments Core Laboratory Systematic review and assessment of ECG’s and Procedural Angiograms

8 CoreValve ADVANCE | Baseline Characteristics

9 CoreValve ADVANCE | Procedural Results

10 CoreValve ADVANCE | Valve Performance

11 CoreValve ADVANCE | Symptom Status

12 CoreValve ADVANCE | 30-day Outcomes

13 CoreValve ADVANCE | 6-month Survival

14 CoreValve ADVANCE | 6-month Survival

15 CoreValve ADVANCE | 6-month Survival

16 CoreValve ADVANCE | 6-month Stroke

17 Summary and Conclusions
The CoreValve ADVANCE study, which is the largest, multicenter, prospective, fully monitored TAVI study, shows that treatment of ‘real world’ inoperable and frail, high-risk patients with the Medtronic CoreValve is: Safe Associated with: an improvement in aortic valve function low stroke and mortality rates at 1 month and 6 months follow-up

18 Thank You CoreValve ADVANCE Study Centers

Download ppt "Axel Linke University of Leipzig Heart Center, Leipzig, Germany"

Similar presentations

Thirty-day Outcomes from the Multi-centre European Pivotal Trial for Transapical Transcatheter Aortic Valve Implantation with a Self-expanding Prosthesis.

Thirty-day Outcomes from the Multi-centre European Pivotal Trial for Transapical Transcatheter Aortic Valve Implantation with a Self-expanding Prosthesis.
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)

Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2012.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Stephen Brecker St. George’s Hospital, London, United Kingdom S Mealing, J Eaton, M Sculpher Oxford Outcomes (ICON), Oxford, United Kingdom Johan Bosmans.

Stephen Brecker St. George’s Hospital, London, United Kingdom S Mealing, J Eaton, M Sculpher Oxford Outcomes (ICON), Oxford, United Kingdom Johan Bosmans.
When Does Baseline Left Ventricular Function Influence Survival Post Transcatheter Aortic Valve Implantation? —The CoreValve Australia New Zealand Study.

When Does Baseline Left Ventricular Function Influence Survival Post Transcatheter Aortic Valve Implantation? —The CoreValve Australia New Zealand Study.
Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis Sabine Bleiziffer German.

Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis Sabine Bleiziffer German.
ACC 2015 Jae K. Oh, MD On Behalf of the US CoreValve Investigators Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression.

ACC 2015 Jae K. Oh, MD On Behalf of the US CoreValve Investigators Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.

Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.

One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
University Heart Center Hamburg

University Heart Center Hamburg
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.

A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.

PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.

The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.

Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.
Axel Linke University of Leipzig Heart Center, Leipzig, Germany Sabine Bleiziffer German Heart Center, Munich, Germany Johan Bosmans University Hospital.

Axel Linke University of Leipzig Heart Center, Leipzig, Germany Sabine Bleiziffer German Heart Center, Munich, Germany Johan Bosmans University Hospital.

Similar presentations

Ads by Google